H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on MEI Pharma to $2 from $5 and keeps a Buy rating on the shares. The analyst cites the deprioritization of zandelisib for the target drop.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MEIP: